EAM Investors’s Kindred Biosciences, Inc. KIN Stock Holding History

EAM Investors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-149,257	Closed	-$1.63M	–	350
2018 Q4	$1.63M	Buy	149,257 +8,631	+6%	+$109K	0.44%	84
2018 Q3	$1.96M	Buy	140,626 +76,743	+120%	+$1.04M	0.29%	151
2018 Q2	$680K	Hold	63,883	–	–	0.11%	259
2018 Q1	$553K	Sell	63,883 -1,604	-2%	-$14.1K	0.09%	270
2017 Q4	$619K	Hold	65,487	–	–	0.11%	269
2017 Q3	$514K	Hold	65,487	–	–	0.07%	278
2017 Q2	$563K	Buy	+65,487	New	+$470K	0.09%	254

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

EAM Investors's KIN Position: Q1 2019 in Review

EAM Investors sold out of Kindred Biosciences, Inc. (KIN) in Q1 2019, closing a stake of 149,257 shares — an estimated $1.63M sold.

EAM Investors first reported a position in KIN in Q2 2017 and held it in 7 quarters. The position peaked at $1.96M in Q3 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q1 2019.

EAM Investors reported no remaining Kindred Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
EAM Investors sold 149,257 Kindred Biosciences, Inc. shares in Q1 2019, an estimated $1.63M.
EAM Investors first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 7 quarters.
EAM Investors's Kindred Biosciences, Inc. position peaked at $1.96M in Q3 2018.
75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2019.

Based on EAM Investors's 13F filing for Q1 2019, filed 13 May 2019.